The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Mexico
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.508
https://www.valueinhealthjournal.com/article/S1098-3015(13)02413-3/fulltext
Title :
The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Mexico
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02413-3&doi=10.1016/j.jval.2013.08.508
First page :
A411
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
487